Tyrosine kinase inhibitors (TKI) are an increasingly used class of anti-cancer agent. Sunitinib (sutent(®), Pfizer™, New York) is standard first-line therapy for patients with metastatic renal cancer. It is associated with a number of toxicities, including thyroid dysfunction. We present a case of sunitinib-induced severe hypothyroidism resulting in cardiac compromise. The case highlights the importance of interval thyroid function monitoring for patients on drugs, such as sunitinib and other TKIs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12032-010-9757-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sunitinib-induced endocapillary proliferative glomerulonephritis with IgA2 deposit in addition to thrombotic microangiopathy: a case report.
BMC Nephrol
August 2024
Renal Division, Peking University First Hospital, Beijing, People's Republic of China.
Background: Sunitinib, a multi-targeted tyrosine kinase inhibitor, is used as a second-line therapy for gastrointestinal stromal tumors (GIST) resistant to imatinib. However, its impact on the vascular endothelial growth factor (VEGF) pathway can lead to significant toxicities, including hypertension and thrombotic microangiopathy (TMA).
Case Presentation: This case report describes a unique instance of a patient with metastatic GIST who developed endocapillary proliferative glomerulonephritis (EPGN) with IgA2 deposits and TMA following sunitinib treatment.
Sunitinib malate induces cell death in adult human cardiac progenitor cells.
Curr Res Toxicol
April 2024
School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Woodhouse Lane, Leeds LS2 9JT, United Kingdom.
Sunitinib malate is known to cause cardiotoxicity in a sub-population of patients, with heart failure seen in more severe cases. Cardiac progenitor cells (CPCs) have been identified in adult human myocardium and contribute to overall tissue maintenance, with previous work identifying negative impacts of sunitinib on these cells. This study aimed to characterise the toxic effects of sunitinib in human CPCs, applying sunitinib concentrations equivalent to clinical plasma levels to these cells .
View Article and Find Full Text PDFSunitinib-induced hyperammonemic encephalopathy in metastatic gastrointestinal stromal tumors: A case report.
World J Clin Cases
November 2023
Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku 160-8582, Tokyo, Japan.
Background: Sunitinib, a multi-targeted tyrosine kinase inhibitor (TKI), has been approved for the salvage treatment of gastrointestinal stromal tumors (GIST). Hyperammonemic encephalopathy is a rare but severe complication of sunitinib use. Here, we present the case of a 66-year-old male with metastatic GIST without underlying liver cirrhosis who developed sunitinib-induced hyperammonemic encephalopathy.
View Article and Find Full Text PDFGut Microbiota and Sunitinib-Induced Diarrhea in Metastatic Renal Cell Carcinoma: A Pilot Study.
Cancer Manag Res
November 2021
Department of Oncology, 900th Hospital of PLA, Fuzong Clinical Medical College of Fujian Medical University, Fuzhou, 350024, People's Republic of China.
Introduction: Sunitinib-induced diarrhea seriously affects the prognosis of patients with metastatic renal cell carcinoma (mRCC) and reduces their quality of life. We aim to explore and find the relationship between sunitinib-induced diarrhea and gut microbiota.
Methods: Feces were collected from 31 mRCC patients receiving sunitinib treatment.
Assessment of Intratumor Heterogeneity in Parametric Dynamic Contrast-Enhanced MR Images: A Comparative Study of Novel and Established Methods.
Front Oncol
September 2021
Group of Radiation Biology and Tumor Physiology, Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Intratumor heterogeneity is associated with aggressive disease and poor survival rates in several types of cancer. A novel method for assessing intratumor heterogeneity in medical images, named the spatial gradient method, has been developed in our laboratory. In this study, we measure intratumor heterogeneity in maps derived by dynamic contrast-enhanced magnetic resonance imaging using the spatial gradient method, and we compare the performance of the novel method with that of histogram analyses and texture analyses using the Haralick method.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!